News

Ketabon Showcases Innovative Ketamine Therapy Advances

Ketabon Showcases Innovative Ketamine Therapy Advances

Ketabon's Innovative Approach to At-Home Ketamine Therapy

Ketabon GmbH, a partnership between HMNC Brain Health and Develco Pharma, is gearing up to make a significant impact at the upcoming European College of Neuropsychopharmacology Congress 2024 in Milan. At this prestigious event, the company plans to unveil groundbreaking advancements in ketamine therapy, particularly for those suffering from treatment-resistant depression (TRD).

Introducing KET01: A New Hope for Patients

Ketabon's main focus will be showcasing KET01, an innovative oral prolonged-release ketamine formulation. This new treatment specifically caters to patients who haven't found relief through conventional depression medications. According to results from a Phase 2 trial of KET01, there were noteworthy improvements in depression severity, all while keeping side effects to a minimum. These findings highlight the promising potential of this new formulation.

Key Findings from Clinical Trials

The trial revealed that a daily dosage of 240mg of KET01 offers swift relief from depressive symptoms, all while maintaining a more favorable side effect profile compared to standard ketamine treatments. This is a hopeful development for individuals exploring alternative methods for managing their depression.

Highlights from the ECNP 2024 Presentation

Key executives from HMNC Brain Health and Develco Pharma, along with researchers from the University Medical Center Hamburg-Eppendorf, will be presenting two important posters during the congress. Their presentations will focus on the tolerability of KET01 and its influence on sleep quality—a concern often linked to existing methods of ketamine therapy.

Session Information

Two engaging sessions are scheduled to take place:

  • Session title: PS01
    Poster presentation number: P1090
    Title: Acute Tolerability of Antidepressant Dose of Oral Prolonged-Release Ketamine (KET01)
    Presenter: A. Damyanova and team
    Track: Mental Conditions
    Date & Time: Sunday, September 22, 2024, from 12:35 to 14:00 CET
  • Session title: PS01
    Poster presentation number: P1084
    Title: Evaluation of Sleep Quality During Treatment with KET01
    Presenter: E. Papanastasiou and team
    Track: Mental Conditions
    Date & Time: Sunday, September 22, 2024, from 12:35 to 14:00 CET

KET01: A User-Friendly Treatment Option

Dr. Hans Eriksson, Chief Medical Officer of Ketabon, emphasizes the importance of these results by pointing out that KET01 enables treatment without major sleep disturbances or sedation—issues often seen with other ketamine formulations. The oral method of administering KET01 offers a unique chance for patients to manage their treatment right from home, which can greatly improve their quality of life without disrupting their daily activities.

The Future of Ketabon and Mental Health Treatments

The Ketabon initiative continues to broaden its horizons, considering the potential expansion of the oral prolonged-release ketamine formulation into other therapeutic areas. These may include anxiety, aggression, PTSD, and panic disorders. Such an expansion could significantly enhance the treatment landscape and provide additional options for patients facing these challenges.

About Ketabon GmbH and Its Partners

As a collaborative venture, Ketabon captures the innovative essence of both HMNC Brain Health and Develco Pharma. HMNC Brain Health is known for its tailored therapy approaches and ground-breaking precision psychiatry, while Develco Pharma brings expertise in advanced oral drug formulations. Together, they aim to redefine treatment methods for mental health.

Frequently Asked Questions

What is KET01?

KET01 is an oral prolonged-release ketamine formulation designed for treating treatment-resistant depression.

When will Ketabon present its findings?

Ketabon will present its findings at the ECNP Congress on September 22, 2024.

What are the outcomes of KET01's Phase 2 trial?

The Phase 2 trial showed rapid improvements in depression severity while maintaining a favorable side effect profile.

How does KET01 compare to traditional ketamine treatments?

KET01 is designed to reduce side effects like sleep disturbances and sedation, which are common with traditional ketamine therapies.

What is the mission of Ketabon?

Ketabon's goal is to develop effective at-home treatments for mental health conditions, enhancing patients' quality of life.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 27

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 1

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 3

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading
Havoc, CSBC Partner for Autonomous Maritime Future

Updated Category News Views 7

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 7

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading
Fermi's Founder Pushes for Board Overhaul: What's Next?

Updated Category News Views 2

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 2

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 4

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 5

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
OneAscent Welcomes Monica Stoudemire as New CCO

Updated Category News Views 5

New Leadership in Compliance Diving straight into the tumultuous sea of securities compliance, OneAscent's got a fresh captain at the helm. Monica Stoudemire's stepped into the Chief Compliance Officer's shoes with a track record that'd make any investor breathe a sigh of relief. After all, blending two decades of on-the-ground experience with regulatory acumen ain't...

Continue Reading
n>

Top 5 Most Recently Viewed Articles

3 Buy-Now-Pay-Later Stocks Set for Holiday Season Gains

Updated Category News Views 74

Exciting Prospects for BNPL Stocks This Holiday Season As we step into the vibrant holiday shopping season, consumers find themselves preparing to splurge on gifts and holiday cheer. With inflationary pressures and high-interest rates shaping spending behavior, many shoppers are seeking alternatives, such as Buy Now Pay Later (BNPL) solutions that cater to their financial...

Continue Reading
Supreme Court Ruling Enhances Corporate Transparency Efforts

Updated Category News Views 141

Supreme Court Ruling Enhances Corporate Transparency Efforts The U.S. Supreme Court has made a significant decision that reinforces the enforcement of federal anti-money laundering regulations. Corporations will now be required to disclose the identities of their true beneficial owners to the U.S. Treasury Department, marking an important shift in corporate governance and...

Continue Reading
Breakthrough Medical Device Addresses Lipohypertrophy in Diabetes

Updated Category News Views 522

Revolutionizing Diabetes Treatment with Embrace Patch Recent clinical trials have shed light on the embrace Active Site Care compression patch, a pioneering medical device that has demonstrated its efficacy in treating lipohypertrophy (LH) in individuals using insulin for diabetes management. This breakthrough reveals how comprehensive care and innovative technology can...

Continue Reading
Sobi Experiences Increase in Shares and Voting Rights

Updated Category News Views 242

Significant Changes in Shares and Votes at Sobi As of the recent announcement, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi) has reached an impressive 357,412,837. This total is made up of 356,000,049 common shares and 1,412,788 C-shares. Notably, the increase of shares and corresponding voting rights is attributed to the recent issuance of...

Continue Reading
Rapid Expansion of the Drug Screening Market Overview

Updated Category News Views 122

Transformation in the Rapid Drug Screening Market The rapid drug screening market is currently experiencing a remarkable transformation, fueled by growing public health concerns, evolving workplace safety regulations, and significant technological advancements. The market, valued at approximately USD 2.4 billion, is expected to expand at a compound annual growth rate...

Continue Reading